NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Forecast, Price & News $1.80 +0.03 (+1.69%) (As of 06/6/2023 ET) Add Compare Share Share Today's Range$1.77▼$1.8250-Day Range$1.44▼$1.9552-Week Range$0.68▼$3.18Volume112,803 shsAverage Volume466,847 shsMarket Capitalization$94.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spero Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside288.9% Upside$7.00 Price TargetShort InterestHealthy1.85% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.05) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector297th out of 981 stocksPharmaceutical Preparations Industry137th out of 464 stocks 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Spero Therapeutics has a forecasted upside of 288.9% from its current price of $1.80.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.85% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 32.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for SPRO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.36% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions57.38% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($1.05) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spero Therapeutics (NASDAQ:SPRO) StockSpero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.Read More Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRO Stock News HeadlinesMay 18, 2023 | finance.yahoo.comTime To Worry? Analysts Are Downgrading Their Spero Therapeutics, Inc. (NASDAQ:SPRO) OutlookMay 16, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q1 2023 Earnings Call TranscriptJune 6, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 12, 2023 | finance.yahoo.comQ1 2023 Spero Therapeutics Inc Earnings CallMay 12, 2023 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business UpdateMay 11, 2023 | msn.comRecap: Spero Therapeutics Q1 EarningsMay 11, 2023 | finance.yahoo.comSpero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business UpdateMay 10, 2023 | seekingalpha.comSpero Therapeutics Q1 2023 Earnings PreviewJune 6, 2023 | Behind the Markets (Ad)WARNING TO ALL U.S. INVESTORSMay 16, 2023... The Day That Will Financially Paralyze 181 Million American Investors... Here are 3 steps to prepare yourself >>>May 10, 2023 | msn.comSpero Therapeutics's Earnings OutlookMay 9, 2023 | americanbankingnews.comSpero Therapeutics (SPRO) Set to Announce Quarterly Earnings on ThursdayMay 4, 2023 | finance.yahoo.comSpero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023April 17, 2023 | finance.yahoo.comSpero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Right But Growth Is Lacking After Shares Rocket 26%April 14, 2023 | finance.yahoo.comSpero Therapeutics to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious DiseasesApril 14, 2023 | americanbankingnews.comQ1 2023 Earnings Forecast for Spero Therapeutics, Inc. (NASDAQ:SPRO) Issued By HC WainwrightApril 13, 2023 | finance.yahoo.comIndustry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%April 13, 2023 | americanbankingnews.comSpero Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.37) Per Share (NASDAQ:SPRO)April 11, 2023 | msn.comHC Wainwright & Co. Reiterates Spero Therapeutics (SPRO) Buy RecommendationApril 11, 2023 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Rating Reiterated by HC WainwrightApril 10, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Spero Therapeutics (SPRO)April 6, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2022 Earnings Call TranscriptApril 1, 2023 | finance.yahoo.comSpero Therapeutics (NASDAQ:SPRO) Is In A Strong Position To Grow Its BusinessMarch 31, 2023 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business UpdateMarch 30, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Beat EstimatesMarch 30, 2023 | finance.yahoo.comSpero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business UpdateMarch 29, 2023 | benzinga.comSpero Therapeutics's Earnings: A PreviewMarch 29, 2023 | markets.businessinsider.comHere's what Wall Street expects from Spero Therapeutics's earningsSee More Headlines SPRO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRO Company Calendar Last Earnings3/30/2023Today6/06/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees146Year Founded2013Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+288.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,420,000.00 Net Margins-50.18% Pretax Margin-50.18% Return on Equity-51.35% Return on Assets-29.39% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio4.42 Sales & Book Value Annual Sales$53.51 million Price / Sales1.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book1.24Miscellaneous Outstanding Shares52,570,000Free Float50,280,000Market Cap$94.63 million OptionableOptionable Beta0.89 Social Links Key ExecutivesAnkit A. MahadeviaPresident, Chief Executive Officer & DirectorTimothy KeutzerChief Operating OfficerSatyavrat ShuklaChief Financial Officer & TreasurerKamal HamedChief Medical OfficerAngela TalleySenior Vice President-Clinical DevelopmentKey CompetitorsVaccitechNASDAQ:VACCTheratechnologiesNASDAQ:THTXSCYNEXISNASDAQ:SCYXGalectin TherapeuticsNASDAQ:GALTBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 80,572 shares on 5/16/2023Ownership: 0.643%Susquehanna International Group LLPSold 66,505 shares on 5/16/2023Ownership: 0.050%Anson Funds Management LPBought 325,254 shares on 5/15/2023Ownership: 6.363%XTX Topco LtdSold 226,873 shares on 5/15/2023Ownership: 0.228%Two Sigma Investments LPSold 7,695 shares on 5/15/2023Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions SPRO Stock - Frequently Asked Questions Should I buy or sell Spero Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks. What is Spero Therapeutics' stock price forecast for 2023? 3 equities research analysts have issued 12-month target prices for Spero Therapeutics' shares. Their SPRO share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 288.9% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts. How have SPRO shares performed in 2023? Spero Therapeutics' stock was trading at $1.73 at the beginning of 2023. Since then, SPRO stock has increased by 4.0% and is now trading at $1.80. View the best growth stocks for 2023 here. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 974,400 shares, a drop of 32.8% from the April 30th total of 1,450,000 shares. Based on an average daily trading volume, of 573,600 shares, the short-interest ratio is presently 1.7 days. View Spero Therapeutics' Short Interest. When is Spero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our SPRO earnings forecast. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Thursday, March, 30th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.95. The firm had revenue of $47.44 million for the quarter, compared to analyst estimates of $1.60 million. Spero Therapeutics had a negative net margin of 50.18% and a negative trailing twelve-month return on equity of 51.35%. What ETFs hold Spero Therapeutics' stock? ETFs with the largest weight of Spero Therapeutics (NASDAQ:SPRO) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). When did Spero Therapeutics IPO? (SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." Who are Spero Therapeutics' major shareholders? Spero Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Anson Funds Management LP (6.36%), Renaissance Technologies LLC (0.78%), Geode Capital Management LLC (0.64%), XTX Topco Ltd (0.23%), Group One Trading L.P. (0.00%) and Two Sigma Investments LP (0.06%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin, Sath Shukla and Timothy Keutzer. View institutional ownership trends. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $1.80. How much money does Spero Therapeutics make? Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $94.63 million and generates $53.51 million in revenue each year. The company earns $-46,420,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. How many employees does Spero Therapeutics have? The company employs 146 workers across the globe. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com. This page (NASDAQ:SPRO) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.